0001640455-21-000040.txt : 20210218 0001640455-21-000040.hdr.sgml : 20210218 20210218194708 ACCESSION NUMBER: 0001640455-21-000040 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210216 FILED AS OF DATE: 20210218 DATE AS OF CHANGE: 20210218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Higgons John Duncan CENTRAL INDEX KEY: 0001581954 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37998 FILM NUMBER: 21651504 MAIL ADDRESS: STREET 1: C/O AGIOS PHARMACEUTICALS, INC. STREET 2: 38 SIDNEY STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jounce Therapeutics, Inc. CENTRAL INDEX KEY: 0001640455 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 454870634 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-259-3840 MAIL ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 wf-form4_161369561285587.xml FORM 4 X0306 4 2021-02-16 0 0001640455 Jounce Therapeutics, Inc. JNCE 0001581954 Higgons John Duncan C/O JOUNCE THERAPEUTICS, INC. 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2021-02-16 4 S 0 200 11.78 D 10113 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 21, 2020. The Reporting Person exercised no discretion with respect to these transactions. /s/ Kim C. Drapkin, Attorney-in-Fact 2021-02-18